LYEL News and Press, Lyell Immunopharma Inc. From 09/03/25

PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second line (2L) setting Ronde-cel is Lyell’s next-generation, dual-t...

Western Uranium & Vanadium Corp (WSTRF) is expected to report for Q2 2025 IceCure Medical Ltd. (ICCM) is expected to report $-0.06 for Q2 2025 TFF Pharmaceuticals Inc - Ordinary Shares (TFFP) is expected to report for quarter end 2025-06-30 Scientific Industries, Inc. (SCND) is ex...

2025-08-12 17:06:18 ET More on Lyell Immunopharma Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement Lyell Immunopharma announces up to $100 million equity private placement Lyell Immunopharma strengthens clinical and commercial capabilit...

2025-08-12 16:55:43 ET More on Lyell Immunopharma Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement Lyell Immunopharma announces up to $100 million equity private placement Read the full article on Seeking Alpha For further detai...

Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphoma Initiated the PiNACLE pivotal trial of LYL314 in patients with large B-cell lymphoma receiving treatment in the ...

Sera Prognostics Inc. (SERA) is expected to report $-0.21 for Q2 2025 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.51 for Q2 2025 Context Therapeutics Inc. (CNTX) is expected to report $-0.06 for Q2 2025 Genco Shipping & Trading ...

Lyell Immunopharma Inc. (LYEL) is expected to report $-3.8 for Q2 2025

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C. , July 29, 2025 /CNW/ -- Equity Insider News Commentary – The average ag...

2025-07-25 08:35:18 ET More on Lyell Immunopharma Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement Lyell Immunopharma strengthens clinical and commercial capabilities with executive appointments Seeking Alpha’s Quant Rating on Ly...

SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placemen...